Contact
Please use this form to send email to PR contact of this press release:
Apexian Pharmaceuticals Announces FDA Acceptance of Phase 1 Protocol to Include Biomarker Measurements and Evaluate the Tolerability and Anti-Tumor Effects of APX3330
TO: